For patients with symptomatic ailment requiring therapy, ibrutinib is frequently suggested based on 4 section III randomized clinical trials comparing ibrutinib with chlorambucil monotherapy106 as well as other usually utilized CIT combinations, specifically FCR, bendamustine plus rituximab and chlorambucil plus obinutuzumab (ClbO).107–109 Ibruti